Par Pharmaceutical Companies, Inc. today announced that it has entered into a supply and distribution agreement with AstraZeneca in the U.S. to market budesonide inhalation suspension, which is a generic form of AstraZeneca's Pulmicort Respules(R) indicated for the maintenance treatment of asthma. Par began shipping 0.25 mg/2 ml and 0.5 mg/2 ml to the trade today.
The details can be read here.
No comments:
Post a Comment